Unicycive Therapeutics (NASDAQ:UNCY) Issues Earnings Results, Beats Estimates By $0.08 EPS

Unicycive Therapeutics (NASDAQ:UNCY – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.08, FiscalAI reports.

Unicycive Therapeutics Price Performance

NASDAQ:UNCY opened at $3.55 on Monday. Unicycive Therapeutics has a one year low of $3.33 and a one year high of $8.74. The company has a market cap of $98.89 million, a PE ratio of -2.03 and a beta of 1.91. The firm’s 50 day simple moving average is $4.19 and its 200 day simple moving average is $5.94.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on UNCY shares. Benchmark reaffirmed a “speculative buy” rating and set a $15.00 target price (up from $13.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 20th. B. Riley Financial reiterated a “buy” rating and issued a $20.00 price target (down from $22.00) on shares of Unicycive Therapeutics in a research note on Wednesday, August 12th. HC Wainwright cut their price objective on Unicycive Therapeutics from $15.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday, September 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a research report on Friday, September 4th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $25.00 target price (down from $37.00) on shares of Unicycive Therapeutics in a report on Thursday, August 13th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.25.

Get Our Latest Analysis on Unicycive Therapeutics

About Unicycive Therapeutics

(Get Free Report)

Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive’s focus on conditions for which treatment options may be limited.

Featured Stories

Earnings History for Unicycive Therapeutics (NASDAQ:UNCY)

Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.